Personalising Treatment for High-Grade Serous Ovarian Carcinoma

被引：18

作者：

Cojocaru, E. ^{[1
]}

Parkinson, C. A. ^{[1
,2
]}

Brenton, J. D. ^{[1
,2
]}

机构：

[1] Cambridge Univ Hosp, Dept Oncol, Cambridge, England

[2] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England

来源：

CLINICAL ONCOLOGY | 2018年 / 30卷 / 08期

关键词：

Genomics; high-grade serous ovarian cancer; PARP inhibitors; RECURRENT EPITHELIAL OVARIAN; PHASE-III TRIAL; OLAPARIB MAINTENANCE THERAPY; CIRCULATING TUMOR DNA; DOUBLE-BLIND; OPEN-LABEL; INTRAPERITONEAL CISPLATIN; FALLOPIAN-TUBE; ONCOLOGY-GROUP; PROGNOSTIC-SIGNIFICANCE;

D O I：

10.1016/j.clon.2018.05.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer is a heterogeneous group of cancers that differ by cell of origin and genomic features. High-grade serous ovarian cancer (HGSOC) is the commonest histiotype and is characterized by extreme genomic complexity and dysregulation of DNA damage repair pathways, particularly homologous recombination deficiency. New insights from molecular profiling into homologous recombination deficiency now offers the credible possibility of personalizing treatment choices for women with HGSOC using poly(ADP-ribose) polymerase inhibitor (PARP) therapy. Although the presence of tumour infiltrating lymphocytes (TILs) in the microenvironment is associated with improved survival in HGSOC, the role of anti-angiogenic and immune checkpoint inhibitor therapy remains unclear. PARP inhibition combined with immunotherapy is an exciting combination strategy for future therapeutic development for women with advanced HGSOC. (C) 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

引用

页码：515 / 524

页数：10

共 92 条

[1] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[2] Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary [J].

Ahmed, Ashour Ahmed ;

Etemadmoghadam, Dariush ;

Temple, Jillian ;

Lynch, Andy G. ;

Riad, Mohamed ;

Sharma, Raghwa ;

Stewart, Colin ;

Fereday, Sian ;

Caldas, Carlos ;

DeFazio, Anna ;

Bowtell, David ;

Brenton, James D. .

JOURNAL OF PATHOLOGY, 2010, 221 (01) :49-56

[3] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[4]

[Anonymous], 2017, NEO ADJUVANT PEMBROL

[5]

[Anonymous], 2016, PLAT AV OLAPARIB 1 L

[6]

[Anonymous], 2018, PHAS 1 2 STUD MED147

[7]

[Anonymous], 2018, STUD AT VERS PLAC CO

[8]

[Anonymous], 2018, OL CED MAL OL COMP S

[9]

[Anonymous], 2017, ATALANTE AT PLAC PHA

[10]

[Anonymous], 2018, STUDY NIRAPARIB MAIN

← 1 2 3 4 5 6 7 8 9 10 →